Reports fourth quarter revenue of $156 million and full year revenue of $639 million
Continued strength in orders with fourth quarter book-to-bill ratio of 1.03
WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024.
Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter. Revenue for the quarter came in as expected with a nice contribution from Metenova of $5 million, very much in-line with our expectations. While there are still pockets of headwinds and challenging macro factors in China, we remain optimistic that our markets will improve as we advance through 2024, with growth accelerating in the second half of the year.”
FOURTH QUARTER BUSINESS HIGHLIGHTS
Positive momentum in new modalities, inclusive of cell and gene therapies, with fourth quarter revenue up 5% sequentially, and up 9% year-over-year
Closed acquisition of mixing innovator Metenova AB, expanding our Fluid Management offering; achieved revenue target of $5 million in the fourth quarter
Launched TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device; a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF)
Strengthened our balance sheet through a private convertible transaction of $600 million aggregate principal amount of 1.00% convertible senior notes
Published our Sustainability report “Making an Impact”, highlighting the company’s progress across numerous environmental, social and governance (ESG) initiatives
FINANCIAL PERFORMANCE
Revenue. For Q4 2023, total revenue was $155.7 million, compared to $186.8 million for 2022. Base revenue (non-GAAP) for Q4 2023 was $142.1 million, compared to $163.0 million for Q4 2022.
For the full year 2023, total revenue was $638.8 million, compared to $801.5 million for 2022. Base revenue (non-GAAP) for 2023 was $599.1 million, compared to $660.5 million for 2022.
Gross profit. For Q4 2023, our gross profit (GAAP) was $67.6 million compared to $96.1 million for Q4 2022. Adjusted gross profit (non-GAAP) for Q4 2023 was $76.5 million compared to $96.1 million for Q4 2022. Gross profit (GAAP) includes $7.7 million in one-time restructuring charges, comprised primarily of inventory adjustments and including asset relocation and severance costs.
For the full year 2023, gross profit (GAAP) was $284.8 million, compared to $455.7 million for the full year 2022. Adjusted gross profit (non-GAAP) for the full year 2023 was $316.5 million, compared to $456.9 million for 2022.
(Loss) Income from operations. For Q4 2023, loss from operations (GAAP) was ($0.9) million, compared to income from operations of $48.8 million for Q4 2022. Adjusted income from operations (non-GAAP) for Q4 2023 was $18.8 million, compared to $41.1 million for Q4 2022.
For the full year 2023, income from operations (GAAP) was $54.6 million, compared to $224.7 million for the full year 2022. Adjusted income from operations (non-GAAP) for the full year 2023 was $94.3 million, compared to $232.2 million for 2022.
Net (loss) income. For Q4 2023, net loss (GAAP) was ($25.5) million, compared to net income (GAAP) of $48.7 million for Q4 2022. Adjusted net income (non-GAAP) for Q4 2023 was $18.8 million compared to $39.1 million for Q4 2022.
For the full year 2023, net income (GAAP) was $41.6 million, compared to $186.0 million for full year 2022. Adjusted net income (non-GAAP) for 2023 was $98.4 million compared to $188.6 million for 2022.
(Loss) Earnings per share. For Q4 2023, loss per share (GAAP) was ($0.46) per basic share and fully diluted basis, compared to $0.85 on a fully diluted basis for Q4 2022. Adjusted earnings per share (non-GAAP) for Q4 2023 was $0.33 on a fully diluted basis, compared to $0.68 for Q4 2022.
For the full year 2023, earnings per share (GAAP) was $0.74 on a fully diluted basis, compared to $3.24 for 2022. Adjusted earnings per share (non-GAAP) for 2023 was $1.75 on a fully diluted basis, compared to $3.28 for 2022.
MARGIN SUMMARY
GAAP Margins
Q4 2023
Q4 2022
FY 2023
FY 2022
Gross Margin
43.4%
51.4%
44.6%
56.9%
Operating (EBIT) Margin
(0.6%)
26.1%
8.5%
28.0%
Adjusted (non-GAAP) Margins
Q4 2023
Q4 2022
FY 2023
FY 2022
Gross Margin
49.1%
51.5%
49.5%
57.0%
Operating (EBIT) Margin
12.1%
22.0%
14.8%
29.0%
EBITDA Margin
16.8%
26.3%
20.0%
30.8%
CASH POSITION
Our cash, cash equivalents and short-term investments at December 31, 2023, were $751.3 million, compared to $623.8 million at December 31, 2022.
FINANCIAL GUIDANCE FOR FISCAL YEAR 2024
Our financial guidance for the fiscal year 2024 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the expected impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.
CURRENT GUIDANCE
(at February 21, 2024)
FY 2024
GAAP
Adjusted (non-GAAP)
Total Reported Revenue
$620M – $650M
$620M – $650M
Year-over-Year Change
(3%) – 2%
(3%) – 2%
Base Revenue Growth
–
(1%) – 4%
Gross Margin
49% – 50%
49% – 50%
Income from Operations
$33M – $38M
$83M – $88M
Operating Margin
5% – 6%
13% – 14%
Other Income (Expense)
$2M – $3M
$18M – $19M
Adjusted EBITDA Margin
–
18% – 19%
Tax Rate on Pre-Tax Income
26%
21%
Net Income
$26M – $30M
$80M – $84M
Earnings Per Share – Diluted
$0.46 – $0.53
$1.42 – $1.49
Our non-GAAP net income guidance for the fiscal year 2024 reflects $54.2 million in adjustments, as referred to in the non-GAAP reconciliation table included later in this press release.
Conference Call and Webcast Access
Repligen will host a conference call and webcast today, February 21, 2024, at 8:30 a.m. ET, to discuss fourth quarter 2023 financial results, corporate developments and financial guidance for the year 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 4526890.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
Non-GAAP Measures of Financial Performance
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: book-to-bill ratios, base business revenue growth, adjusted gross profit, adjusted gross margin and adjusted operating margin; adjusted cost of sales; adjusted R&D expense; adjusted SG&A expense; adjusted pre-tax income; adjusted income from operations; adjusted net income; adjusted earnings per share-diluted; adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides base revenue and base revenue growth rates, which exclude COVID-related revenue, and the impact of acquisition revenue for current year periods that have no prior year comparables, to facilitate a comparison of its current revenue performance. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency, which exclude the impact of foreign currency translation, in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.
The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: inventory step-up charges; acquisition and integration costs; restructuring charges including the costs of severance; inventory adjustments and accelerated depreciation among other charges; contingent consideration related to the Company’s acquisitions; intangible amortization costs; loss on extinguishment of debt; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.
NOTE:
All reconciliations of above GAAP figures (reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.
Forward-Looking Statement
This release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this release which are not strictly historical statements, including, among others; any express or implied statements or guidance regarding current or future financial performance and position, including our year 2024 financial guidance and related assumptions; expected demand in the markets in which we operate (including the belief that such markets will improve and the impact of such improvement on our business); the expected performance of our business; planned efficiencies and results from our restructuring and rebalancing activities; the expected performance and success of our strategic partnerships and integration of our acquired businesses, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks associated with our restructuring activities and our ability to successfully rebalance our organization; our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds, including to achieve our adjusted 2024 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate any acquired businesses (including Metenova and FlexBiosys) into our business and achieve the expected benefits of such acquisitions; that demand for our products could continue to decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; the lasting effects of COVID-19 on our business operations and the operations of our customers and suppliers; our volatile stock price; and other risks detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on Form 10-K for the year ended December 31, 2022 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and current reports on Form 8-K, as well as our upcoming Annual Report on Form 10-K for the year ended December 31, 2023. Actual results may differ materially from those Repligen contemplated by these forward-looking statements; therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except share and per share data)
Three Months Ended December 31,
Twelve Months Ended December 31,
2023
2022
2023
2022
Revenue:
Product revenue
$
155,471
$
186,515
$
638,381
$
801,183
Royalty and other revenue
272
247
383
353
Total revenue
155,743
186,762
638,764
801,536
Costs and expenses:
Cost of product revenue
88,136
90,700
353,922
345,830
Research and development
10,285
11,113
42,722
43,936
Selling, general and administrative
57,512
53,237
218,113
215,829
Contingent consideration
697
(17,125
)
(30,569
)
(28,729
)
156,630
137,925
584,188
576,866
(Loss) Income from operations
(887
)
48,837
54,576
224,670
Investment income
6,023
4,016
24,135
6,978
Interest expense
(1,138
)
(270
)
(1,951
)
(1,162
)
Loss on extinguishment of debt
(12,676
)
–
(12,676
)
–
Amortization of debt issuance costs*
(6,702
)
(455
)
(8,075
)
(1,815
)
Other income (expenses), net
6,623
858
8,123
(9,531
)
(Loss) income before income taxes
(8,757
)
52,986
64,132
219,140
Income tax provision
16,731
4,257
22,555
33,181
Net (loss) income
$
(25,488
)
$
48,729
$
41,577
$
185,959
(Loss) earnings per share:
Basic
$
(0.46
)
$
0.88
$
0.75
$
3.35
Diluted*
$
(0.46
)
$
0.85
$
0.74
$
3.24
Weighted average shares outstanding:
Basic
55,815,666
55,542,248
55,719,860
55,460,232
Diluted*
55,815,666
57,105,172
56,377,319
57,455,275
*Under ASU 2020-06, the Company is required to reflect the dilutive effect of the 2019 Notes by application of the if-converted method. Prior to filing the Second Supplemental Indenture on March 4, 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion principal in cash and only the premium in shares of the Company’s common stock. Therefore, from March 5, 2022 to March 31, 2022 the Company included 980,525 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Under the if-converted method, the Company was also required to exclude amortization of debt issuance cost and interest charges applicable to the convertible debt from the numerator of the diluted EPS calculation for the period from January 1, 2022 to March 4, 2022, assuming the interest on convertible debt was never recognized for that period. For the twelve months ended December 31, 2022 the Company excluded amortization of debt issuance costs and interest charges for the period January 1, 2022 to March 4, 2022 of $0.4 million (tax effected) from the numerator.
Balance Sheet Data:
December 31, 2023
December 31, 2022
Cash, cash equivalents and marketable securities
$
751,323
$
623,757
Working capital
952,881
593,922
Total assets
2,824,411
2,524,658
Long-term obligations
695,046
209,762
Accumulated earnings
438,849
397,272
Stockholders’ equity
1,971,203
1,910,700
REPLIGEN CORPORATION
RECONCILIATIONS OF GAAP to NON-GAAP FINANCIAL MEASURES
(Unaudited, amounts in thousands, except percentage and per share data)
Reconciliation of Reported Revenue Growth to Organic Revenue Growth (Non-GAAP)
Three Months Ended December 31,
Twelve Months Ended December 31,
2023
2023
REPORTED REVENUE GROWTH
(17%)
(20%)
Less: Acquisition Growth
3%
1%
Less: Currency Exchange
1%
0%
ORGANIC REVENUE GROWTH (NON-GAAP)
(21%)
(21%)
Reconciliation of Total Revenue (GAAP) to Base Revenue (Non-GAAP)
Three Months Ended December 31,
% Change
Twelve Months Ended December 31,
% Change
2023
2022 (2)
2023 v 2022
2023
2022 (2)
2023 v 2022
GAAP TOTAL REVENUE
$
155,743
$
186,762
(17
%)
$
638,764
$
801,536
(20
%)
COVID Revenue
(8,007
)
Leave a Reply